CanProbe is a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC) to create a Canadian Centre of Excellence for the development, translation, utilization and commercialization of radiopharmaceuticals. CanProbe leverages the strengths of its partners and their affiliates.

icon of computer with cells on it

Icon of a cell

Icon of hand and petri dish

About

CanProbe provides access to specialized expertise that supports the development of new radiopharmaceuticals, with proven experience translating products to the clinical setting, and world-class, GMP, manufacturing capabilities that operate in accordance with FDA, Health Canada and European regulations.

These radiopharmaceuticals are part of an advanced imaging technology that uses medical isotopes to assess and treat patients at a cellular level. Using imaging radiopharmaceuticals, physicians can detect diseases earlier and more accurately monitor the effectiveness of treatments. Targeted therapeutic radiopharmaceuticals can be used to provide personalized treatment of cancers.

Product Pipeline

The safety and efficacy of these investigational products have not been fully established and they have not been approved by Health Canada as commercial products for medicinal use. These products can only be used under an approved clinical trial application (CTA).

Investigational Products

  • [F-18]-DCFPyL
  • [F-18]-FAZA
  • [F-18]-FLT

Press Release

CanProbe joins ARTMS inc and POINT BioPharma in advancing Ga-68 Imaging

Services

Translational & Clinical Research

Development and commercialization of radiopharmaceuticals in support of clinical and research programs.

Process support and analytical chemistry development for preclinical studies or clinical trials.

Regulatory and clinical research support, including for local researchers using our tracers.

Development and validation of process and methods and GMP manufacturing for clinical trial supply.

Technical transfer of existing methods to enable the manufacture of radiopharmaceuticals for clinical trials.

Access to radioisotopes under the Canadian Nuclear Safety Commission (CNSC) licence such as F-18, Ga-68 or Lu-177. Contact us for the complete list.

Radiopharmaceutical Manufacturing

Production of CanProbe products and contract manufacturing on behalf of industry partners.

Distribution of radiopharmaceutical products both locally and abroad.

CanProbe has supported over 40 clinical trials with various investigational products

CanProbe has manufactured over 16,000+ patient doses since 2016

CanProbe has relationships with several pharmaceutical clients to manufacture a variety of radiopharmaceuticals

Team

CanProbe is governed by a Board of Directors with members drawn from the University Health Network UHN) and the Centre for Probe Development and Commercialization (CPDC). Board members oversee the joint venture and ensure the successful operation of CanProbe.

CanProbe Board of Directors:

Photo of Bruno

Bruno Paquin

President, CanProbe
Business Development, Senior Director, CPDC

LUKE BRZOZOWSKI

Secretary, CanProbe
Senior Director, Techna and Diagnostics Innovation, UHN

Photo of Angela

Angela Lauretani

Director, CanProbe
Senior Director, Finance & Administration, CPDC

Photo of Julia

Julia Publicover

Director, CanProbe
Program Manager, Techna Institute, UHN

Dr. Ur Metser

Ur Metser

Director, CanProbe
Division Head of Molecular Imaging, UHN

Photo of Anne Goodbody

Anne Goodbody

Director, CanProbe
Chief Regulatory Officer, CPDC

CanProbe Leadership

Photo of David Green

David Green

Site Lead, Techna Institute, UHN

Photo of Constantinos Economou

Constantinos Economou

Director, Manufacturing Operations CPDC

Careers

Join Our Team

Quality Control Team Lead (Chemistry QC and Analytical Development)

Full Time
Toronto, Ontario

The Centre for Probe Development and Commercialization (CPDC) is a leading provider, on a global basis, of next-generation radiopharmaceuticals that are used daily for the detection and treatment of human diseases such as cancer. The Centre is seeking applicants for the position of Team Lead, Quality Control Operations position. CPDC offers career growth and development in a highly entrepreneurial environment. CPDC offers medical and dental benefits, sick days and more.

Radiopharmaceuticals are perishable products that require just-in-time manufacturing on a daily or weekly basis to ensure supply demands are met without interruption. CPDC’s success in the radiopharmaceutical industry results from the ability of our talented and committed staff to develop reproducible processes that yield high quality products while adhering to international regulations governing nuclear safety, transportation of dangerous goods and pharmaceutical manufacturing.

This position will be based in Toronto, Ontario, Canada. Reporting to the Quality Control Manager / Supervisor

The Team Lead of Quality Control Operations utilizes the chemistry or biochemistry skills and supervisory expertise to work hands-on with their team, and to lead a QC team in planning work schedules and assignments to ensure the successful completion of tasks in a timely fashion while ensuring consistent high quality in a constant effort to provide best support to the organization with professionalism and integrity.

If you require accommodation for your application or interview, please contact Human Resources directly at 905.525.9140 ext. 21112 or by email at careers@imagingprobes.ca

We thank all those who apply but only candidates selected for interviews will be contacted.

contact

CanProbe is located in Toronto’s Discovery District with facilities in the University Health Network’s Toronto General Hospital.

If you are interested in working with CanProbe to take your radiopharmaceutical study to the next level, contact us at info@canprobe.ca

Partners

UHN Logo

CPDC Logo

UHN Research and Innovation Cores Logo

Techna Logo

QIPCM Logo

STTARR Logo